Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis

We conducted a systematic review and meta-analysis to assess various antidiabetic agents' association with mortality in patients with type 2 diabetes (T2DM) who have coronavirus disease 2019 (COVID-19). We performed comprehensive literature retrieval from the date of inception until February 2,...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2021-09, Vol.12, p.708494
Main Authors: Kan, Chengxia, Zhang, Yang, Han, Fang, Xu, Qian, Ye, Tongtong, Hou, Ningning, Sun, Xiaodong
Format: Article
Language:English
Subjects:
antidiabetic agents
COVID-19
COVID-19 - complications
diabetes
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Endocrinology
Humans
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
mortality
Risk Assessment
type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We conducted a systematic review and meta-analysis to assess various antidiabetic agents' association with mortality in patients with type 2 diabetes (T2DM) who have coronavirus disease 2019 (COVID-19). We performed comprehensive literature retrieval from the date of inception until February 2, 2021, in medical databases (PubMed, Web of Science, Embase, and Cochrane Library), regarding mortality outcomes in patients with T2DM who have COVID-19. Pooled OR and 95% CI data were used to assess relationships between antidiabetic agents and mortality. Eighteen studies with 17,338 patients were included in the meta-analysis. Metformin (pooled OR, 0.69; =0.001) and sulfonylurea (pooled OR, 0.80; =0.016) were associated with lower mortality risk in patients with T2DM who had COVID-19. However, patients with T2DM who had COVID-19 and received insulin exhibited greater mortality (pooled OR, 2.20; =0.002). Mortality did not significantly differ (pooled OR, 0.72; =0.057) between DPP-4 inhibitor users and non-users. Metformin and sulfonylurea could be associated with reduced mortality risk in patients with T2DM who have COVID-19. Furthermore, insulin use could be associated with greater mortality, while DPP-4 inhibitor use could not be. The effects of antidiabetic agents in patients with T2DM who have COVID-19 require further exploration. PROSPERO (identifier, CRD42021242898).
ISSN:1664-2392
1664-2392
DOI:10.3389/fendo.2021.708494